TY - JOUR T1 - RECODE: RCT on effectiveness of integrated COPD management in primary care JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p4990 AU - Annemarije Kruis AU - Melinde Boland AU - Pim Assendelft AU - Jacobijn Gussekloo AU - Apostolos Tsiachristas AU - Maureen Rutten AU - Jaap Sont AU - Niels Chavannes Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p4990.abstract N2 - Background: There is insufficient evidence of the (cost)effectiveness of primary care COPD disease management programmes.Aim and objective: To evaluate the (cost)effectiveness of an ICT-supported, integrated, multidisciplinary disease management program for primary care COPD patients. We expect health care providers to improve inter-collegial communication, personalized treatment planning and better adherence to guidelines. As a result, we expect quality of care and quality of life in patients to improve.Methods: The study has a two-group cluster-randomized design in which 40 clusters of primary care teams are being randomized. Required sample size is 1080 COPD patients, in accordance with GOLD. Few exclusion criteria are applied. The intervention consists of a multidisciplinary course (2 days) in which primary care givers (general practitioners, practice nurses, physiotherapists, dieticians) within a particular region are trained as a team. The course will emphasize efficient task delegation within the team, active patient involvement in treatment planning, and designing time-contingent practice plans. Primary outcome is difference in health status as measured by Clinical COPD Questionnaire (CCQ). Programme costs, costs of healthcare utilization and productivity loss will also be calculated. Primary endpoint is at 12 months, while total study duration is two years.Results: Until now 496 patients have been included, which preliminary baseline means of FEV1/FVC ratio 56%, FEV1 65% predicted, CCQ score 1.65, MRC score 2 and EQ-5D score 0.71.Conclusion: The RECODE study is a cluster randomized trial which will provide insight in the cost-effectiveness of this particular primary care COPD disease management programme. ER -